New Triple-Drug attack before surgery shows promise for breast cancer

NCT ID NCT07492394

Recruiting now Disease control Sponsor: Hebei Medical University Fourth Hospital Source: ClinicalTrials.gov ↗

First seen Mar 26, 2026 · Last updated May 15, 2026 · Updated 8 times

Summary

This study tests whether adding a third drug (entinostat) to a two-drug combination (dalpiciclib and letrozole) before surgery can shrink tumors more effectively in people with HR-positive, HER2-negative early breast cancer. About 60 women will receive either the three-drug or two-drug regimen for about 6 months before surgery. The goal is to see if the triple combination leads to higher rates of tumor disappearance or significant shrinkage, potentially allowing more breast-conserving surgeries.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

The Fourth Hospital of Hebei Medical University
RECRUITING

Shijiazhuang, Hebei, 050000, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

BREAST CANCER